Who to call at CNS Pharmaceuticals, Inc., and when
Fundz watches for the moments CNS Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day CNS Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CNS Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CNS Pharmaceuticals, Inc.. With Fundz connected, it knows.
CNS Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
cnspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
CNS Pharmaceuticals' stockholders approved at the November 17, 2025 Annual Meeting an increase in 2020 Equity Plan shares by 114,916 (to 115,061 total) and an increase in authorized common stock from 25,000,000 to 300,000,000 and preferred stock from 416,667 to 5,000,000, with the charter amendment filed November 20, 2025. The larger authorized share base gives the company substantial room for future equity financing and creates potential dilution for existing holders.
Key Takeaways
Authorized common stock rises twelvefold, from 25,000,000 to 300,000,000 shares, and was effective with the Nevada filing on November 20, 2025.
Authorized preferred stock increases from 416,667 to 5,000,000 shares, adding flexibility for future preferred issuances.
2 more takeaways
Related Filings (7)
7 more filings from CNS Pharmaceuticals, Inc. in the last 90 days
Filing Overview
What This Means
CNS Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.